- Nano Express
- Open Access
Biocompatibility of Graphene Oxide
- Kan Wang†1,
- Jing Ruan†1,
- Hua Song1,
- Jiali Zhang1,
- Yan Wo1,
- Shouwu Guo1Email author and
- Daxiang Cui1Email author
© Wang et al. 2010
Received: 2 August 2010
Accepted: 6 August 2010
Published: 21 August 2010
Herein, we report the effects of graphene oxides on human fibroblast cells and mice with the aim of investigating graphene oxides' biocompatibility. The graphene oxides were prepared by the modified Hummers method and characterized by high-resolution transmission electron microscope and atomic force microscopy. The human fibroblast cells were cultured with different doses of graphene oxides for day 1 to day 5. Thirty mice divided into three test groups (low, middle, high dose) and one control group were injected with 0.1, 0.25, and 0.4 mg graphene oxides, respectively, and were raised for 1 day, 7 days, and 30 days, respectively. Results showed that the water-soluble graphene oxides were successfully prepared; graphene oxides with dose less than 20 μg/mL did not exhibit toxicity to human fibroblast cells, and the dose of more than 50 μg/mL exhibits obvious cytotoxicity such as decreasing cell adhesion, inducing cell apoptosis, entering into lysosomes, mitochondrion, endoplasm, and cell nucleus. Graphene oxides under low dose (0.1 mg) and middle dose (0.25 mg) did not exhibit obvious toxicity to mice and under high dose (0.4 mg) exhibited chronic toxicity, such as 4/9 mice death and lung granuloma formation, mainly located in lung, liver, spleen, and kidney, almost could not be cleaned by kidney. In conclusion, graphene oxides exhibit dose-dependent toxicity to cells and animals, such as inducing cell apoptosis and lung granuloma formation, and cannot be cleaned by kidney. When graphene oxides are explored for in vivo applications in animal or human body, its biocompatibility must be considered.
In recent years, a lot of engineered nanomaterials are fabricated endlessly and investigated for their applications [1–6], and nanomaterials' biosafety has caused more and more attention from governments and scientific communities [7, 8]. For example, carbon nanotubes, as the special carbon nanomaterials, have been investigated for their effects on the cells, animals and environment, and evaluated for their biosafety [9–13]. Graphene is a flat monolayer of carbon atoms tightly packed into a two-dimensional (2D) honeycomb lattice and is a basic building block for graphitic materials of all other dimensionalities with unique physical, chemical, and mechanical properties [14, 15]. Graphene and graphene oxide (GO) layers have become a hotspot so far and have been actively investigated to build new composite materials [16, 17]. These novel nanomaterials have great potential in applications such as electrochemical devices [18, 19], energy storage [20, 21] catalysis , adsorption of enzyme , cell imaging and drug delivery , as well as biosensors  However, up to date, no report is closely associated with biosafety of GO in cells or live biosystems. Here we are the first to report the effects of GO on human normal cells and mice, our results show that GO exhibits dose-dependent toxicity to cells and mice, which highly suggests that the biocompatibility of GO must be considered when the GO is applied for biomedical engineering.
Synthesis and Characterization of GO
Graphene oxide (GO) was prepared from natural graphite powder by the modified Hummers method . Graphite (2 g 500 mesh) and sodium nitrate (1 g) were added to a 250-mL flask at 0°C. Concentrated H2SO4 (50 mL) was then added slowly with stirring below 5°C. The mixture was stirred for 30 min and 0.3 g of KMnO4 was added in small portions below 10°C. The reaction mixture was stirred for an additional 30 min and 7 g of KMnO4 was added to the mixture respectively over 1 h below 20°C. After the temperature of the mixture warmed to 35 ± 3°C and stirred for 2 h, 90 mL of water was slowly dripped into the paste, causing an increase in temperature to 70°C and the diluted suspension was stirred at this temperature for another 15 min. Then, it was further treated with a mixture of H2O2 (30%, 7 mL) and water (55 mL). The resulting suspension turned bright yellow, and the warm suspension (about 40°C) was filtered, resulting in a yellow–brown filter cake. The cake was washed for three times with a warm solution of 3% aqueous HCl (150 mL), followed by drying at 40°C for 24 h in vacuo. Finally, the GO was obtained by ultrasonication of as-made graphite oxide in water for 1 h. The resulting homogeneous yellow–brown dispersion was tested to be stable until now. GO was analyzed by the FT-IR technique showed the presence of GO, using Fourier transform infrared (EQUINOX 55, Bruker, Germany) spectrometer. Furthermore, the structure and the texture of GO were observed by transmission electron microscopy (TEM) and AFM (Figure 2), which are JEOL JEM-2010 TEM and Nanoscope MultiMode SPM (Veeco, American).
Effects of GO on Human Fibroblast Cells
where A570(sample) is absorbance intensity at 570 nm in the presence of GO, and A570(control) is absorbance intensity at 570 nm in the absence of GO.
The cell attachment assay was performed as previously described . Essentially, 6-well plates were coated with fibrinogen (5 μg/mL) and vitronectin (1.5 μg/mL) in DPBS. Cells were harvested, washed three times with serum-free minimal essential medium with Eargle's salt and resuspended in attachment solution (calcium- and magnesium-free Hanks' balanced salt solution, 20 mM HEPES, 1 mg/mL heat-inactivated BSA, 1 mM CaCl2 and 1 mM MgCl2). Cells (1 × 104) were added to each well and allowed to culture for 1–5 days at 37°C in a humidified 5% CO2 incubator. These plates of respective 5, 10, 20, 50 and 100 μg/mL GO-treated cells were cultured for 1–5 days, and 1 control plate was set up (1 × 104 cells were added into each well, which was treated with 0.5% DMSO vehicle and allowed to culture for 1–5 days at 37°C in a humidified 5% CO2 incubator) and were centrifuged for 10 min at the speed of 4,000 rpm. Unattached cells were washed with Hanks' balanced salt solution. The number of remaining attached cells after centrifugation was quantified spectrophotometrically at 405 nm in triplicate . Cell adhesion ability (%) = the number of GO-treated adhesive cells/the number of control adhesive cells.
Human fibroblast cells (HDF) were treated for 5 days with different concentrations of GO: 5, 10, 20, 50, and 100 μg/mL. After incubation, cells were lysed in protein lysis buffer. Equal amounts of sample lysate were separated by sodium dodecylsulfatepolyacrylamide gel electrophoresis (SDS–PAGE) and electrophoretically transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore). The membrane was blocked with 0.1% BSA in TBST buffer and incubated overnight at 4°C with specific primary antibodies. Subsequently, the membrane was washed with TBST buffer and incubated with horseradish peroxidase-conjugated secondary antibodies. Enhanced chemiluminescence kits were used (Amersham, ECL kits) . In order to confirm whether GO can stimulate HDF cells secrete small molecular proteins, HDF cells were cultured for 5 days in essential medium without 10% fetal calf serum with the aim of excluding mistaking fetal calf serum proteins as secreted small molecular proteins.
HDF was treated with 20 μg/mL GO and cultured in a humidified 5% CO2 balanced air incubator at 37°C for 24 h, then fixed cells with 2.5% glutaraldehyde solution and embedded with epoxy resin, finally made the ultrathin cell specimen and observed the specimen with TEM.
Effects of GO on Mice
All animal experiments performed in compliance with the local ethics committee. Kunming mice (female, 28–30 g, 4–5 weeks old) were obtained from the Shanghai LAC Laboratory Animal Co. Ltd., Chinese Academy of Sciences (Shanghai, China) and housed in positive-pressure air-conditioned units (25°C, 50% relative humidity) on a 12:12-h light/dark cycle. The mice were allowed to acclimate at this facility for 1 week before being used in the experiment. Each mouse was exposed to the GO suspension via a single tail vein injection. The mice were killed at 1, 7, and 30 days post exposure, and their organs, including heart, liver, spleen, stomach, kidneys, lungs and brain, were collected. For conventional histology, tissues were collected immediately after killing, fixed in 10% formaldehyde, embedded in paraffin, cut into 20-μm-thick section, stained with hematoxylin and eosin, and examined by light microscopy. Three mice were used for negative control.
Each experiment was repeated three times in duplicate. The results were presented as mean ± SD.
Statistical differences were evaluated using the t-test and considered significance at P < 0.05.
Results and Discussion
Characterization of GO
Effects of GO on Human Fibroblast (HDF) Cells
Effects of GO on Cell Adhesive Proteins
Effects of GO on Cell Morphology
Effects of GO on Lifespan of Mice
Regarding the effects of GO on mice, we used tail vein injection pathway to evaluate the in vivo toxicity. The mice were injected with 0 mg (control group), 0.1 mg (low dose group, LD), 0.25 mg (medium dose group, MD), and 0.4 mg (high dose group, HD) GO per mouse. After 1 day, 1 week, and 1 month exposure, the mice were killed by the method of cervical vertebra displace, and then used histopathology to evaluate inflammation degree of the mouse organs.
Injection dose of GO at 0.1 and 0.25 mg per mouse did not cause mortality of exposed mice, and showed no obvious clinical toxic signs, and the body weight of treated mice accordingly increased with the raise time increasing. However, 4 of 9 mice treated with 0.4 mg per mouse died (1/3 in the 1-day group, 1/3 in the 7-day group and 2/3 in the 30-day group). All deaths occurred 1–7 days after injection of the GO. The deaths were generally preceded by lethargy, inactivity, and body-weight losses. Histopathology of lung tissues showed that major airways of four mice were mechanically blocked by the GO conglomeration, which led to suffocation in 15% of the GO-exposed mice, and was not evidence of pulmonary toxicity of GO. In addition, the survival mice treated with 0.4 mg of GO for 24 h appeared weakness and lost 10% of body weights within first week, this symptoms disappeared after one week, as evidenced by subsequent normal eating behavior and weight increase.
Effects of GO on Important Organs
Regarding the biodistribution of GO in mice, as we observed, GO mainly located in lung, liver and spleen, no GO was found in the brain tissues, which highly suggests that GO cannot get through blood–brain barrier. Few GO was observed in kidney of mice, which highly suggests that GO is very difficult to be exited out by pathway of kidney, we speculate that GO mainly is expelled out by liver secretion into bile tract system.
The Potential Mechanism of Effects of GO on Human Cells
As mentioned earlier, we clearly observed that graphene oxides with dose of less than 20 μg/mL did not exhibit toxicity to human fibroblast cells, and the dose of more than 50 μg/mL exhibits obvious cytotoxicity such as decreasing cell adhesion, inducing cell apoptosis, entering into lysosomes, mitochondrion, endoplasm, and cell nucleus. Similar phenomena were also observed in other cell lines such as human gastric cancer MGC803, human breast cancer MCF-7, MDA-MB-435, and liver cancer HepG2 cell lines (data not shown), which highly suggest that GO exhibits obvious toxicity to human normal cells or tumor cells. According to our results, we suggest the possible mechanism of GO's cytotoxicity as follows: GO in medium attach to the surface of human cells, providing a stimuli signal to the cells. The signal is transduced inside the cells and the nucleus, leading to down-regulation of adhesion-associated genes and corresponding adhesive proteins, resulting in decrease in cell adhesion and causing cells to detach, float, and shrink in size. At the same time, GO enters into cytoplasm by endocytosis pathway, mainly located in the lysosomes, mitochondrion, endoplasm and cell nucleus, may disturb the course of cell energy metabolism and gene transcription and translation, and finally result in cell apoptosis or death.
The Possible Mechanism of Effects of GO on Mice
As we observed, graphene oxides under low dose (0.1 mg) and middle dose (0.25 mg) did not exhibit obvious toxicity to mice, under high dose (0.4 mg) exhibited chronic toxicity such as 4/9 mice death and lung granuloma formation, mainly located in lung, liver, spleen and kidney, almost could not be cleaned by kidney. The possible mechanism of effects of GO on mice is suggested as follows: when GO enters into mouse body by vessel injection, directly enter into blood circulation system, as one kind of foreign body, which should be recognized and tracked by immune cells, GO quickly distributes into lung, liver, spleen, and kidney, but cannot enter into brain due to blood–brain barrier. When GO enters into lung tissues, provides a stimulating signal to lung cells, under synergic action of lung cells and immune cells, GO is captured and wrapped by immune cells, finally results in lung granuloma formation, GO in liver, spleen, and kidney may cause corresponding inflammation. Because of flake-shapes of GO, GO is very difficult to be kicked out by kidney, thus stay in liver, spleen, and kidney for long term, at the lower dose, these organs such as liver, spleen, and kidney can tolerate and maintain their normal function, at higher dose, lot of GO in liver, spleen, and kidney can damage the balance and badly affect the function of these organs, result in failure of organ function and death of mice. Regarding the effects of immune cells on GO in vivo in mice, the possible mechanism is not clarified well and still needs further research.
In conclusion, our primary studies have indicated that GO could produce cytotoxicity in dose- and time-dependent means, and can enter into cytoplasm and nucleus, decreasing cell adhesion, inducing cell floating and apoptosis. GO can enter into lung tissues and stop there and induce lung inflammation and subsequent granulomas highly dependent on injected dose. Exposures to GO may induce severe cytotoxicity and lung diseases. It should be the first report. Although GO has been investigated for biomedical applications such as cell imaging and drug delivery [30–35], because of GO's long-term stay in kidney and being very difficult to be cleaned by kidney, therefore, GO may not own good application prospect in human body. How to decrease or abolish the toxicity of GO is still a challengeable task for in vivo biomedical application. Further work will focus on investigating the possible mechanism of interaction between GO and immune cells in human body or mice.
This work was supported by the National Natural Science Foundation of China (Nos. 20803040 and 20471599), Chinese 973 Project (2010CB933901), 863 Key Project (2007AA022004), New Century Excellent Talent of Ministry of Education of China (CET-08-0350, Special Infection Diseases Key Project of China (2009ZX10004-311), Shanghai Science and Technology Fund (10XD1406100, 1052nm04100 and No. 072112006-6).
- Song H, He R, Wang K, Ruan J, Bao C, Li N, Ji J, Cui D: Biomaterials. 2010, 31: 2302. 10.1016/j.biomaterials.2009.11.067View ArticleGoogle Scholar
- Huang P, Kong Y, Li Z, Gao F, Cui D: Nanoscale Res Lett. 2010, 5: 949. 10.1007/s11671-010-9587-0View ArticleGoogle Scholar
- Hu H, Yang H, Huang P, Cui D, Peng Y, Zhang J, Lu F, Lian J, Shi D: Chem Commun. 2010, 46: 3866. 10.1039/b927321bView ArticleGoogle Scholar
- Tian F, Prina-Mello A, Estrada G, Beyerle A, Möller W, Schulz H, Kreyling W, Stoeger T: Nano Biomed Eng. 2009,1(1):13. 10.5101/nbe.v1i1.p13-26View ArticleGoogle Scholar
- Li H, Zhang Y, Huang W: Nano Biomed Eng. 2009,1(1):32.Google Scholar
- Huang P, Lin J, Li Z, Hu H, Wang K, Gao G, He R, Cui D: Chem Commun. 2010, 46: 4800. 10.1039/c0cc00307gView ArticleGoogle Scholar
- Rice RF: Science. 2003, 300: 243.Google Scholar
- Dagani R: Chem Eng News. 2003, 81: 30. 10.1021/cen-v081n017.p030View ArticleGoogle Scholar
- Bermudez E, Mangum JB, Wong BA, Asgharian B, Hext PM, Warheit DB, Everitt JI: Toxicol Sci. 2004, 77: 347. 10.1093/toxsci/kfh019View ArticleGoogle Scholar
- Pan B, Cui D, Ozkan CS, Ozkan M, Xu P, Huang T, Liu F, Chen H, Li Q, He R, Gao F: J Phys Chem C. 2008, 112: 939. 10.1021/jp068920cView ArticleGoogle Scholar
- Cui D, Tian F, Ozkan CS, Wang M, Gao H: Toxicol Lett. 2005, 155: 77. 10.1016/j.toxlet.2004.08.015View ArticleGoogle Scholar
- Lam CW, James JT, McCluskey R, Hunter RL: Toxicol Sci. 2004, 77: 126. 10.1093/toxsci/kfg243View ArticleGoogle Scholar
- Wang Z, Ruan J, Cui D: Nanoscale Res Lett. 2009, 4: 593. 10.1007/s11671-009-9292-zView ArticleGoogle Scholar
- Geim AK, Novoselov KS: Nat Mater. 2007, 6: 183. 10.1038/nmat1849View ArticleGoogle Scholar
- Kopelevich Y, Esquinazi P: Adv Mater. 2007, 19: 4559. 10.1002/adma.200702051View ArticleGoogle Scholar
- Li X, Wang X, Zhang L, Lee S, Dai H: Science. 2008, 319: 1229. 10.1126/science.1150878View ArticleGoogle Scholar
- Szabo T, Berkesi O, Dekany I: Carbon. 2005, 43: 3186. 10.1016/j.carbon.2005.07.013View ArticleGoogle Scholar
- Park SJ, Lee KS, Bozoklu G, Cai WW, Nguyen ST, Ruoff RS: ACS Nano. 2008, 2: 572. 10.1021/nn700349aView ArticleGoogle Scholar
- Cai DY, Yusoh K, Song M: Nanotechnology. 2009, 20: 085712. 10.1088/0957-4484/20/8/085712View ArticleGoogle Scholar
- Dreyer DR, Park SJ, Bielawski CW, Ruoff RS: Chem Soc Rev. 2010, 39: 228. 10.1039/b917103gView ArticleGoogle Scholar
- Margine ER, Bocquer ML, Blasé X: Nano Lett. 2008, 8: 3315. 10.1021/nl801718fView ArticleGoogle Scholar
- Dikin DA, Stankowich S, Zimney EJ, Piner RD, Dommerr GHB, Evmenenko G, Nguyen SBT, Ruoff RS: Nature. 2007, 448: 06016. 10.1038/nature06016View ArticleGoogle Scholar
- Zhang JL, Yang HJ, Shen GX, Cheng P, Zhang JY, Guo SW: Chem Commun. 2010, 46: 1112. 10.1039/b917705aView ArticleGoogle Scholar
- Sun X, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S, Dai H: Nano Res. 2008, 1: 203. 10.1007/s12274-008-8021-8View ArticleGoogle Scholar
- Liu Y, Yu D, Zeng C, Miao Z, Dai L: Langmuir. 2010, 26: 6158. 10.1021/la100886xView ArticleGoogle Scholar
- Hummers WS, Offeman RE: J Am Chem Soc. 1958, 80: 1339. 10.1021/ja01539a017View ArticleGoogle Scholar
- Xu Y, Liu Z, Zhang X, Wang Y, Tian J, Huang Y, Ma Y, Zhang X, Chen Y: Adv Mater. 2009, 21: 1275. 10.1002/adma.200801617View ArticleGoogle Scholar
- Cai WW, Zhu YW, Li XS, Piner RD, Ruoff RS: Appl Phys Lett. 2009, 95: 123115. 10.1063/1.3220807View ArticleGoogle Scholar
- Cui D, Jin GQ, Gao T, Sun T, Tian R, Estrada G, Gao H, Sarai A: Cancer Epidem Biomark Prev. 2004,13(7):1136.Google Scholar
- Lomeda JR, Doyle CD, Kosynkin DV, Hwang W, Tour JM: J Am Chem Soc. 2008, 130: 16201. 10.1021/ja806499wView ArticleGoogle Scholar
- Muszynski R, Seger B, Kamat PV: J Phys Chem C. 2008, 112: 5263. 10.1021/jp800977bView ArticleGoogle Scholar
- Jeong HK, Lee YP, Jin MH, Kim ES, Bae JJ, Lee YH: Chem Phys Lett. 2009, 470: 255. 10.1016/j.cplett.2009.01.050View ArticleGoogle Scholar
- Zhang JL, Zhang F, Yang HJ, Huang XL, Liu H, Zhang JY, Guo SW: Langmuir. 2010, 26: 6083. 10.1021/la904014zView ArticleGoogle Scholar
- Akiko Y, Shuzo M, Norio M, Masae S: J Biomed Mater Res. 2000, 50: 114. 10.1002/(SICI)1097-4636(200005)50:2<114::AID-JBM4>3.0.CO;2-6View ArticleGoogle Scholar
- Lotz MM, Burdsal CA, Erickson HP, Mc clay DR: J Cell Biol. 1989, 109: 1795. 10.1083/jcb.109.4.1795View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.